Greenphire has announced the launch of EnvisiX to address the budgeting challenges experienced by global sponsors and CROs during study start-up. The new budget development solution aims to streamline trial initiation for sponsors and CROs and eliminate guesswork during the budgeting process to deliver a smarter, more efficient workflow.
EnvisiX integrates with eClinicalGPS, Greenphire’s site payment solution, enabling simplicity and efficiency throughout a trial from budget creation and negotiation to management, execution, and tracking of global investigator grants.
“Greenphire is dedicated to engineering workflow and data solutions that transform business processes, reducing administrative burden and improving process effectiveness at each step of the clinical trial,” said Jim Murphy, Greenphire CEO. “With EnvisiX, stakeholders gain visibility and control over historically manual and fragmented budget build and negotiation workflows, ensuring improved speed and accuracy along the way.”
EnvisiX will enable sponsors and CROs to:
“For years, sponsors and CROs have expressed dissatisfaction with their study start-up processes. We have developed EnvisiX as a direct response to frustrations with the current workflows and solutions available in the market today,” said Kyle Cunningham, Chief Product Officer at Greenphire. “Our mission was to ensure that EnvisiX provides our customers with a streamlined and user-friendly experience for building a budget and ultimately to enable maximized confidence, defensibility and end-to-end efficiency via a direct integration and feedback loop with eClinicalGPS, the industry’s leading site payment solution.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.